User login
Key clinical point: Tapinarof cream 1% applied once daily (QD) displayed significant efficacy after 4 weeks along with good tolerability and limited systemic exposure in patients with extensive plaque psoriasis.
Major finding: At day 29, the mean Psoriasis Area Severity Index score changed significantly with a mean percentage change from baseline of −59.56% (95% CI, −73.53% to −45.59%) and the tapinarof plasma concentration remained below the quantification level (< 50 pg/mL) in the majority (67.9%) of patients; 17 patients reported no irritation and 2 had mild irritation at the application site.
Study details: Findings are from a phase 2a trial involving 21 adult patients with extensive plaque psoriasis (20% or more body surface area involvement) who applied tapinarof cream 1% QD for 29 days.
Disclosures: The study was supported by Dermavant Sciences, Inc. Some of the authors, including the lead author, declared serving as an employee or investigator for Dermavant Sciences, Inc.
Source: Jett JE et al. Am J Clin Dermatol. 2021 Oct 28. doi: 10.1007/s40257-021-00641-4.
Key clinical point: Tapinarof cream 1% applied once daily (QD) displayed significant efficacy after 4 weeks along with good tolerability and limited systemic exposure in patients with extensive plaque psoriasis.
Major finding: At day 29, the mean Psoriasis Area Severity Index score changed significantly with a mean percentage change from baseline of −59.56% (95% CI, −73.53% to −45.59%) and the tapinarof plasma concentration remained below the quantification level (< 50 pg/mL) in the majority (67.9%) of patients; 17 patients reported no irritation and 2 had mild irritation at the application site.
Study details: Findings are from a phase 2a trial involving 21 adult patients with extensive plaque psoriasis (20% or more body surface area involvement) who applied tapinarof cream 1% QD for 29 days.
Disclosures: The study was supported by Dermavant Sciences, Inc. Some of the authors, including the lead author, declared serving as an employee or investigator for Dermavant Sciences, Inc.
Source: Jett JE et al. Am J Clin Dermatol. 2021 Oct 28. doi: 10.1007/s40257-021-00641-4.
Key clinical point: Tapinarof cream 1% applied once daily (QD) displayed significant efficacy after 4 weeks along with good tolerability and limited systemic exposure in patients with extensive plaque psoriasis.
Major finding: At day 29, the mean Psoriasis Area Severity Index score changed significantly with a mean percentage change from baseline of −59.56% (95% CI, −73.53% to −45.59%) and the tapinarof plasma concentration remained below the quantification level (< 50 pg/mL) in the majority (67.9%) of patients; 17 patients reported no irritation and 2 had mild irritation at the application site.
Study details: Findings are from a phase 2a trial involving 21 adult patients with extensive plaque psoriasis (20% or more body surface area involvement) who applied tapinarof cream 1% QD for 29 days.
Disclosures: The study was supported by Dermavant Sciences, Inc. Some of the authors, including the lead author, declared serving as an employee or investigator for Dermavant Sciences, Inc.
Source: Jett JE et al. Am J Clin Dermatol. 2021 Oct 28. doi: 10.1007/s40257-021-00641-4.